Ethylphenidate
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Ethylphenidate (ethyl 2-phenyl-2-piperidin-2-ylacetate) — Gogaine, Burst — is a synthetic stimulant of the phenidate class. It is the ethyl ester structural analog of methylphenidate, with stronger dopamine selectivity.[1] It blocks dopamine reuptake in the brain, producing stimulation, euphoria, and a strong drive to redose.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
methylphenidate, amphetamine, cocaine +1 moremethylphenidate, amphetamine, cocaine, dopaminergic stimulants show less
EPH was first identified in 1999 as a byproduct formed when Methylphenidate and alcohol are taken together.[2] It appeared on research chemical markets around 2011; by 2014–2015, widespread injection in Scotland drove a major HIV outbreak among people who inject drugs.[3] It is now Schedule I in the United States and explicitly controlled in the UK, Canada, Germany, and Austria.[4]
Subjective effects include Stimulation, Euphoria, focus enhancement, and a powerful urge to redose. The experience is more recreational than functional — longer and less intensely euphoric than cocaine, and less useful for cognition than methylphenidate, with the drive to re-administer often outrunning the reward.[5][6] Anxiety, paranoia, and scattered thinking are common at higher doses.
Dependence liability is moderate; nearly all documented fatalities involved combinations with depressants.[7][8] The dominant risk is the compulsive redosing urge — escalating doses compound cardiovascular strain and psychological destabilization, and the drive to re-administer often persists after the reward has faded.[9] No clinical trials exist; current understanding rests on forensic case series, animal studies, and user reports.
History[edit]
Discovery
Ethylphenidate was not designed as a drug. It was first identified in 1999 in postmortem blood from people who had taken methylphenidate with alcohol — the liver converts the combination into EPH as a byproduct.[2] Patrick et al. synthesized all four stereoisomers in 2005, establishing EPH as pharmacologically distinct with potent DAT blockade.[1]
Emergence as a novel psychoactive substance
EPH appeared on research chemical markets around 2011, sold under names like "Gogaine" and "Burst" and formally flagged by European drug monitoring authorities that year.[10] Between 2013 and 2015, it became widely injected among existing drug users in Scotland,[8][11] contributing to the largest HIV outbreak among people who inject drugs in the UK in thirty years.[3]
Scheduling
Countries moved to control EPH incrementally: Austria in 2012, Germany in 2013, the UK via a Temporary Class Drug Order in 2015,[12] and the United States in November 2024.[4] Hospital presentations related to EPH declined significantly after controls were introduced.[13]
The name "ethylphenidate" comes directly from its structure: an ethyl ester variant of methylphenidate. The street names "Gogaine" and "Burst" reflect its early marketing as a cocaine substitute. EPH was also found in UK prison supply chains, where paper impregnated with novel psychoactive substances was used to circumvent institutional drug controls.[14]
Chemistry[edit]
Structure
Ethylphenidate belongs to the phenidate family of stimulants — compounds built on a piperidine ring bonded to a phenylacetate ester. It is structurally nearly identical to methylphenidate, differing by a single carbon at the ester group: an ethyl replaces a methyl.
This shift makes EPH more selective for the DAT over the NET.[1][6] Its molecular formula is C₁₅H₂₁NO₂ (molecular weight 247.33 g/mol).
Pharmacology[edit]
Mechanism of action
EPH blocks the DAT, preventing the brain from clearing dopamine from synapses.[9] It is more selective for dopamine than methylphenidate, which inhibits both dopamine and norepinephrine reuptake more evenly.[15][6] This dopamine focus shapes the experience: more reward-centered and less functionally arousing than methylphenidate.
The active form binds dopamine transporters approximately 13 times more potently than cocaine.[1] Its effect on norepinephrine is weaker; its effect on serotonin is negligible.[1][6][16]
Pharmacokinetics
EPH is broken down primarily by an enzyme called carboxylesterase 1, producing ritalinic acid as the main metabolite.[17] No human pharmacokinetic studies have been conducted — peak levels, half-life, and bioavailability remain uncharacterized.
Neuroscience[edit]
Reward circuit activation
EPH amplifies dopamine signaling in the brain's reward circuit by blocking reuptake in the nucleus accumbens.[9] This is the pathway most directly tied to pleasure, motivation, and reinforcement. Repeated exposure elevated a molecular marker called ΔFosB across reward-circuit brain regions in adolescent mice — the kind of change linked to compulsive drug-seeking.[9]
Prefrontal function and the inverted-U
Dopamine elevation in the prefrontal cortex drives the focus enhancement seen at lower doses.[5] More is not better: once dopamine rises past an optimal level, performance reverses — attention sharpens, then fragments, and indecisiveness replaces clarity.[5] This is why EPH feels clarifying at low doses and destabilizing at high ones.
EPH's greater dopamine selectivity compared to methylphenidate raises the question of whether chronic use produces distinct long-term brain changes. Repeated EPH exposure impaired spatial learning in adolescent mice without corresponding changes in brain growth factors[9] — the mechanism is unexplained. Prolonged mental health effects persisting after cessation have been documented in users,[18] but their neurobiological basis remains unknown.
Subjective Effects[edit]
The ethylphenidate experience centers on dopaminergic reward — clean stimulation and mood lift at lower doses, giving way to anxious, scattered thinking as amounts increase. The defining feature across all doses is a compulsive compulsive redosing urge that outlasts the pleasure of each subsequent dose.[5]
Relative to cocaine, EPH produces a longer, less intensely euphoric stimulation with a stronger compulsive character. Compared to methylphenidate, it is more recreational and less useful for focus or productivity, reflecting EPH's stronger dopamine preference and weaker noradrenergic contribution.[15][6]
Effect Grid
Clear stimulation with euphoria, pronounced focus enhancement, and thought acceleration. Motivation enhancement is apparent — tasks feel rewarding and purposeful. Communication flows readily, and sociability enhancement is well established. Time alteration may compress perceived duration.
Appetite suppression is strong. Cardiovascular effects become apparent: elevated heart rate and blood pressure are noticeable. Bruxism and jaw tension may emerge. Vasoconstriction produces noticeably cold hands and feet. Dehydration sensation and excessive sweating are common. Insomnia is expected for several hours after dosing.
The compulsive redosing urge emerges clearly at this tier and constitutes the primary behavioral risk. The drive to re-administer may exceed the subjective reward of subsequent doses.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity enhancement · Tinnitus · Auditory hallucinations · External hallucinations · Shadow people
Shadow people
Dry mouth · Heart rate perception changes · Insomnia · Pupil dilation · Body high · Excessive sweating · Muscle tension · Physical fatigue · Restlessness · Dehydration sensation · Bodily lightness · Headache · Nausea · Sexual arousal enhancement · Bruxism · Breathing alteration · Dizziness · Respiratory stimulation · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Motor control enhancement · Abnormal heartbeat · Constipation · Motor control impairment · Trembling · Tactile hallucination
Pupil dilation · Body high · Excessive sweating · Muscle tension · Physical fatigue · Restlessness · Dehydration sensation · Bodily lightness · Headache · Nausea · Sexual arousal enhancement · Bruxism · Breathing alteration · Dizziness · Respiratory stimulation · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Motor control enhancement · Constipation · Motor control impairment · Trembling · Tactile hallucination
Cognitive euphoria · Information processing enhancement · Analysis enhancement · Motivation enhancement · Immersion enhancement · Language enhancement · Memory enhancement · Thought organization · Aesthetic enhancement · Cognitive flexibility · Multiple thought streams · Novelty enhancement · Pattern recognition enhancement · Creativity enhancement · Motivation suppression · Cognitive dysphoria · Cognitive impairment · Confusion · Thought disorganization · Thought loops · Thought deceleration
Immersion enhancement · Language enhancement · Memory enhancement · Thought organization · Aesthetic enhancement · Cognitive flexibility · Multiple thought streams · Novelty enhancement · Pattern recognition enhancement · Creativity enhancement · Motivation suppression · Cognitive dysphoria · Cognitive impairment · Confusion · Thought disorganization · Thought loops · Thought deceleration
Emotional enhancement · Anhedonia · Dysphoria · Emotional lability
Communication enhancement · Self-control enhancement · Sociability enhancement · Ego inflation · Depersonalization
Depersonalization
Timeline
Gradual awareness of mild stimulation — slight alertness increase and subtle mood shift. Effects remain sub-threshold for the first portion of this window.
Building stimulation with emerging focus enhancement and mood lift. Heart rate begins to rise and appetite suppression becomes noticeable.
Full stimulation, euphoria, and focus enhancement. Compulsive redosing urge is strongest during this phase. Cardiovascular effects (elevated heart rate, blood pressure) are most apparent.
Gradual decline in stimulation. Irritability, cognitive fatigue, and restlessness may emerge as dopaminergic stimulation fades. Appetite remains suppressed.
Residual wakefulness and appetite suppression persist. Depression, anhedonia, and physical fatigue are common. Cognitive fatigue may impair concentration.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- methylphenidate · amphetamine · cocaine
Toxicity
Acute toxicity
No lethal dose or toxic threshold has been established for ethylphenidate in humans.
Two postmortem case series provide the main reference data. Parks et al. reviewed 19 EPH-associated deaths in Scotland (2013–2014); EPH was named in the cause of death in five cases.[8] Maskell et al. reported seven fatalities in England (2013–2015); only one case involved EPH as the sole detected substance.[7]
Cardiovascular effects
EPH raises heart rate, blood pressure, and body temperature.[5] Abnormal heartbeat appears in community reports. No controlled cardiovascular safety data exist.
Injection-related harms
Injecting EPH powder carries serious risks of blood vessel damage and tissue injury.[19] A surge in intravenous EPH use in Scotland from 2014 to 2015[11] was identified as a major driver of the largest HIV outbreak among people who inject drugs in the UK in thirty years.[3]
EPH powder is not formulated for injection. This route adds risks of particulate blockage in blood vessels, abscess formation, and bloodborne virus transmission.
Psychological risks
Compulsive redosing is the dominant psychological risk. Users described an overwhelming urge to re-administer that frequently overrode their own intentions to stop.[5]
Higher doses produce anxiety, paranoia, cognitive fragmentation, and indecisiveness.[5] Prolonged psychiatric effects persisting after cessation have been documented.[18] In animal models, repeated exposure elevated a molecular marker in reward-circuit brain regions associated with compulsive drug-seeking.[9]
Tolerance & dependence
No human studies have directly characterized EPH tolerance or dependence.
Tolerance to euphoric and stimulatory effects is expected with repeated use, based on pharmacological class. Estimated tolerance half-life (~5 days) and full reset (~1.5 weeks) are structural-structural analog inferences, not EPH-specific measurements.inferred Cross-tolerance with other dopaminergic stimulants is expected.
Dependence liability is moderate. Animal models show conditioned reward responses at low doses and molecular changes in reward regions consistent with compulsive use.[9] User reports corroborate moderate psychological dependence.[5] No formal withdrawal has been characterized, though post-cessation psychiatric effects have been reported.[18]
Drug interactions
Ethanol
When methylphenidate and alcohol are combined, the body produces EPH as a byproduct and methylphenidate blood levels rise 40–100% through competitive enzyme inhibition.[20][21] When EPH is taken directly with alcohol, the same enzyme is expected to slow EPH's breakdown — elevating blood concentrations and prolonging duration.[17] Combined stimulant–alcohol use carries additive cardiovascular risk.safety citation needed
Tramadol
Both EPH and tramadol lower the seizure threshold. Combining them creates additive seizure risk. The combination is rated as potentially lethal.[8][7]safety citation needed
MDMA
Combining EPH with MDMA produces additive cardiovascular stimulation — elevated heart rate, blood pressure, and body temperature — with potential for dangerous overheating.safety citation needed
Polydrug mortality patterns
Most documented EPH deaths involved co-administration with depressants: benzodiazepines appeared in 15 of 19 Scottish cases, opioids in 11, and methadone in 8.[8][7] Stimulant effects can mask depressant toxicity — respiratory failure or cardiovascular collapse can arrive without warning.
Contraindications
Heart conditions
Pre-existing heart disease, uncontrolled high blood pressure, structural heart abnormalities, and irregular heartbeat history are absolute contraindications. EPH raises heart rate, blood pressure, and body temperature.[5]inferred
MAOIs
Combining EPH with MAOIs — drugs that slow the body's breakdown of epinephrine-related chemicals — can trigger a dangerous blood pressure spike.inferred
Seizure disorders
EPH lowers the seizure threshold. Active seizure disorders and medications that also reduce seizure threshold are relative contraindications.inferred
Pregnancy
No reproductive toxicity data exist for EPH. Use during pregnancy is contraindicated by analogy with Methylphenidate.inferred
Harm Reduction[edit]
Forms & Identification
Ethylphenidate is most commonly encountered as a white crystalline powder or as its hydrochloride salt. Because it was sold through the research chemical market, purity and composition have varied significantly between batches and vendors. Reagent testing provides a first-line screen; laboratory testing services offer the most reliable identification where available.
Guidelines
- Test the substance before use — reagent kits provide a first-line screen, but laboratory testing offers definitive identification
- Pre-measure doses and separate remaining material before the session begins — do not keep bulk supply accessible
- Set a firm redosing limit before onset and communicate it to a trusted companion
- Stay hydrated but avoid overhydration — drink water steadily rather than in large volumes
- Eat a meal before use; stimulant appetite suppression makes post-onset eating unlikely
- Avoid injection — oral and insufflated routes carry substantially less risk than intravenous administration
Set & Setting
The compulsive redosing urge is EPH's defining risk and should shape every decision about context. Using alone increases the likelihood of unchecked redosing. The presence of a sober companion or a pre-set dose limit can interrupt the binge pattern.
Physical separation from supply is one of the most effective harm reduction interventions. Keeping bulk material out of reach during a session reduces the ease of re-administration when the urge hits.
Aftercare & integration. The EPH comedown brings fatigue, low mood, irritability, and appetite rebound effect. Prioritize sleep — stimulant disruption of sleep architecture is cumulative, and recovery requires uninterrupted rest rather than sedative assistance where possible.
Eat nutrient-dense food as appetite returns. Avoid caffeine and other stimulants in the 24–48 hours following use. After a binge, expect a proportionally more severe and longer comedown. Persistent low mood, anxiety, or sleep disruption beyond 72 hours warrants consultation with a healthcare provider.
Recovery & Support
Repeated EPH use can develop into a pattern of compulsive bingeing that is difficult to interrupt without external support. The compulsive redosing urge distinguishes EPH from many stimulants — the drive to re-administer persists long after the subjective reward has diminished.
Support resources include SAMHSA's National Helpline (1-800-662-4357), local harm reduction services, and stimulant-specific peer support groups. Professional help is warranted when use has become difficult to control, when binges are increasing in frequency or duration, or when mental health symptoms persist between sessions.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizure, loss of consciousness, or body temperature hot enough to feel through clothing indicate a medical emergency. Severe confusion, paranoid ideation with self-harm risk, or inability to communicate also require immediate help.
Immediate steps:
- 1. Call emergency services
- 2. Place the person in the recovery position if unconscious but breathing
- 3. Keep them cool — remove excess clothing, apply cool water to forehead and neck
- 4. Do not restrain unless there is immediate danger of self-harm
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (ethylphenidate or stimulant), estimated amount, time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Ethylphenidate was initially uncontrolled in most jurisdictions, sold openly as a "research chemical" in the early 2010s. Scheduling proceeded incrementally, driven by forensic identification in fatality cases and injection-related harm clusters.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | DEA final rule effective 21 November 2024[4] |
| United Kingdom | Banned (Psychoactive Substances Act 2016) | Temporary Class Drug Order from 10 April 2015;[12] extended June 2016;[22] subsequently covered by blanket PSA ban from 26 May 2016 |
| Germany | Anlage II BtMG (Schedule II) | Controlled under Narcotics Act since 17 July 2013 |
| Austria | Controlled (NPSG) | New Psychoactive Substances Act, effective 1 January 2012 |
| Canada | Schedule III (CDSA) | Added to Controlled Drugs and Substances Act on 5 May 2017 |
| Australia | Analogue control | Captured as methylphenidate analogue under existing legislationcitation needed |
| Sweden | Controlled | Referenced in ACMD documentation as controlled[12] |
| Denmark | Controlled | Referenced in ACMD documentation as controlled[12] |
Analogue considerations
In jurisdictions without specific EPH scheduling, structural analog control provisions may apply. EPH is a direct structural analog of methylphenidate. Prior to its explicit Schedule I placement in November 2024, the US Federal Analogue Act could be invoked against EPH when intended for human consumption. In Australia, EPH is reportedly captured under analogue provisions, though specific scheduling instruments have not been independently verified.citation needed
references
- [1]
- [2] ^abMarkowitz JS, Logan BK, Diamond F, Patrick KS (1999) Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion. — Journal of Clinical Psychopharmacology PMID:10440465
- [3] ^abcMcAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, Gunson RN, Metcalfe R, Milosevic C, Taylor A, Munro A, Hutchinson SJ (2019) Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. — The Lancet HIV doi:10.1016/s2352-3018(19)30036-0
- [4]
- [5]
- [6]